Successful Management of Subacute Cutaneous Lupus Erythematous with Litifilimab, a Plasmacytoid Dendritic Cell-Directed Therapy

Summary: This report discusses a case of subacute cutaneous lupus erythematosus in a 52-year-old woman resistant to conventional treatments such as hydroxychloroquine and methotrexate, who was enrolled in a phase II trial for litifilimab, an antibody that targets plasmacytoid dendritic cells (pDCs). Litifilimab significantly reduced the patient’s lesions, clearing her skin after eight weeks of treatment. The drug works by inhibiting pDC activation, reducing lupus-related inflammatory responses. The trial showed promising results, with further studies ongoing.